Pharmacological approaches to discovery and development of new mucolytic agents

Advanced Drug Delivery Reviews

Volumn 54, Issue 11, 2002, Pages 1475-1490

  King, Malcolm ^a   Rubin, Bruce K ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Airway mucus; Mucoactive agents; Mucociliary clearance; Mucolytic agents; Mucus secretion

Indexed keywords

CELLS; DRUG PRODUCTS; MOLECULAR WEIGHT; PHYSICAL PROPERTIES; PULMONARY DISEASES;

MUCOUS CELLS;

PATIENT TREATMENT;

GLYCOPROTEIN; ION; LIPID; MUCOLYTIC AGENT; PROTEIN; WATER;

COUGHING; HUMAN; IN VITRO STUDY; LUNG CLEARANCE; LUNG DISEASE; MUCOUS CELL; MUCUS SECRETION; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW;

EID: 0037027914     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00156-4     Document Type: Article

References (88)

1. Rubin B.K., Tomkiewicz R.P., King M. Mucoactive agents: Old and new. Wilmott R.W. The Pediatric Lung. 1997;155-179 Birkhäuser, Basel. Chapter 7.
2. Rose M.C., Gendler S.J. Airway mucin genes and gene products. Rogers D.F., Lethem M.I. Airway Mucus: Basic Mechanisms and Clinical Perspectives. 1997;41-66 Birkhäuser, Basel. Chapter 3.
3. Davies J.R., Carlstedt I. Respiratory tract mucins. Salathé M. Cilia and Mucus: From Development to Respiratory Defense. 2001;167-178 Marcel Dekker, New York.
4. Verdugo P. Polymer biophysics of mucus in cystic fibrosis. Baum G. Cilia, Mucus and Mucociliary Interactions. 1998;167-190 Marcel Dekker, New York.
5. R.C. Boucher, State of the art: Human airway ion transport, Am. J. Respir. Crit. Care Med. 150 (1994) 271-281&581-593.
6. King M., Rubin B.K. Rheology of airway mucus: Relationship with clearance function. Takashima T., Shimura S. Airway Secretion: Physiological Bases for the Control of Mucous Hypersecretion. 1994;283-314 Marcel Dekker, New York. Chapter 7.
7. Tomkiewicz R.P., Kishioka C., Freeman J., Rubin B.K. DNA and actin filament ultrastructure in cystic fibrosis sputum. Baum G. Cilia, Mucus and Mucociliary Interactions. 1998;333-341 Marcel Dekker, New York. Chapter 34.
8. Sheehan J.K., Richardson P.S., Fung D.C., Howard M., Thornton D.J. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am. J. Respir. Cell. Mol. Biol. 13:1995;748-756.
9. Kishioka C., Okamoto K., Kim J., Rubin B.K. Regulation of secretion from mucous and serous cells in the excised ferret trachea. Respir. Physiol. 126:2001;163-171.
10. Mak J.C., Baraniuk J.N., Barnes P.J. Localization of muscarinic receptor subtype mRNAs in human lung. Am. J. Respir. Cell. Mol. Biol. 7:1992;344-348.
11. Takeyama K., Jung B., Shim J.J., Burgel P.R., Dao-Pick T., Ueki I.F., Protin U., Kroschel P., Nadel J.A. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am. J. Physiol.: Lung Cell. Mol. Physiol. 280:2001;L165-L172.
12. Homolya L., Watt W.C., Lazarowski E.R., Koller B.H., Boucher R.C. Nucleotide-regulated calcium signaling in lung fibroblasts and epithelial cells from normal and P2Y(2) receptor (-/-) mice. J. Biol. Chem. 274:1999;26454-26460.
13. Schuh J.M., Blease K., Hogaboam C.M. CXCR2 is necessary for the development and persistence of chronic fungal asthma in mice. J. Immunol. 168:2002;1447-1456.
14. Davril M., Degroote S., Humbert P., Galabert C., Dumur V., Lafitte J.J., Lamblin G., Roussel P. The sialylation of bronchial mucins secreted by patients suffering from cystic fibrosis or from chronic bronchitis is related to the severity of airway infection. Glycobiology. 9:1999;311-321.
15. Li J.D., Feng W., Gallup M., Kim J.H., Gum J., Kim Y., Basbaum C. Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc. Natl. Acad. Sci. USA. 95:1998;5718-5723.
16. King M., Rubin B.K. Mucus physiology and pathophysiology: Therapeutic aspects. Derenne J.P., Whitelaw W.A., Similowski T. Acute Respiratory Failure in COPD (Lung Biology in Health and Disease Series). 1996;391-411 Marcel Dekker, New York. Chapter 13.
17. Blake J.R. On the movement of mucus in the lung. J. Biomech. 8:1975;179-190.
18. King M., Agarwal M., Shukla J.B. A planar model for mucociliary transport: Effect of mucus viscoelasticity. Biorheology. 30:1993;49-61.
19. Girod S., Galabert C., Lecuire A., Zahm J.M., Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr. Pulmon. 13:1992;22-27.
20. King M. Role of mucus viscoelasticity in cough clearance. Biorheology. 24:1987;589-597.
21. King M., Brock G., Lundell C. Clearance of mucus by simulated cough. J. Appl. Physiol. 58:1985;1776-1782.
22. King M., Zahm J.M., Pierrot D., Vaquez-Girod S., Puchelle E. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough. Biorheology. 26:1989;737-745.
23. Dasgupta B., King M. Molecular basis for mucolytic therapy. Can. Respir. J. 2:1995;223-230.
24. Hovenberg H.W., Davies J.R., Carlstedt I. Different mucins are produced by the surface epithelium and the submucosa in human trachea: Identification of MUC5AC as a major mucin from the goblet cells. Biochem. J. 318:1996;319-324.
25. King M., Rubin B.K. Mucus controlling agents: Past and present. Rau J.L. Aerosolized Drugs for the Respiratory Tract. 1999;575-594 Respiratory Care Clinics North America.
26. Klein A., Strecker G., Lamblin G., Roussel P. Structural analysis of mucin-type O-linked oligosaccharides. Methods Mol. Biol. 125:2000;191-209.
27. Chace K.V., Leahy D.S., Martin R., Carbelli R., Flux M., Sachdev G.P. Respiratory mucous secretions in patients with cystic fibrosis: Relationship between levels of highly sulfated mucin component and severity of the disease. Clin. Chim. Acta. 132:1983;143-155.
28. Rahmoune H., Lamblin G., Lafitte J.J., Galabert C., Filliat M., Roussel P. Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis. Am. J. Respir. Cell. Mol. Biol. 5:1991;315-320.
29. Puchelle E., Zahm J.M., Polu J.M., Sadoul P. Drug effects on viscoelasticity of mucus. Eur. J. Respir. Dis. 61:1980;195-208.
30. Rubin B.K., MacLeod P.M., Sturgess J., King M. Recurrent respiratory infections in a child with fucosidosis: Is the mucus too thin for effective transport? Pediatr. Pulmonol. 10:1991;304-309.
31. Thornton D.J., Davies J.R., Carlstedt I., Sheehan J.K. Structure and biochemistry of human respiratory mucins. Rogers D.F., Lethem M.I. Airway Mucus: Basic Mechanisms and Clinical Perspectives. 1997;19-39 Birkhäuser, Basel. Chapter 2.
32. Bell S.L., Khatri I.A., Xu G., Forstner J.F. Evidence that a peptide corresponding to the rat Muc2 C-terminus undergoes disulphide-mediated dimerization. Eur. J. Biochem. 253:1998;123-131.
33. Perez-Vilar J., Hill R.L. The strusture and assembly of secreted mucins. J. Biol. Chem. 274:1999;31751-31754.
34. Sheffner A.L., Medler E.M., Jacobs L.W., Sarrett H.P. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis. 90:1964;721-729.
35. Ventresca G.P., Cicchetti Ferrari V. Acetylcysteine. Braga P.C., Allegra L. Drugs in Bronchial Mucology. 1989;77-102 Raven Press, New York.
36. Roberts G.P. The role of disulfide bonds in maintaining the gel structure of bronchial mucus. Arch. Biochem. Biophys. 173:1976;528-537.
37. Sheffner A.L. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetylcysteine. Ann. NY Acad. Sci. 106:1963;298-310.
38. Davis S.S., Deverell L.C. The effect of sulphydryl compounds and cross-linking agents on the viscous and viscoelastic properties of mucus. Biorheology. 12:1975;225-232.
39. Martin R., Litt M., Marriott C. The effect of mucolytic agents on the rheologic and transport properties of canine tracheal mucus. Am. Rev. Respir. Dis. 121:1980;495-500.
40. M. King, Mucus, mucociliary clearance and coughing, in: D.V. Bates (Ed.), Respiratory Function in Disease. 3rd Edition, Saunders, Philadelphia, 1989, pp. 69-78.
41. Tomkiewicz R.P., App E.M., De Sanctis G.T., Coffiner M., Maes P., Rubin B.K., King M. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: Airway epithelial function and mucus changes in dog. Pulmon. Pharmacol. 8:1995;259-265.
42. App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Maes P., Vanderbist F., King M. Efficacy, safety and tolerability of chronic inhalation therapy with Nacystelyn vs. placebo in cystic fibrosis patients. Am. J. Respir. Crit. Care Med. 155:1997;A199.
43. App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur. Respir. J. 19:2002;294-302.
44. Sudo E., King M. Effect of lysine on tracheal mucus rheology and secretion in mice. Am. J. Respir. Crit. Care Med. 159:1999;A686.
45. Lethem M.I., James S.L., Marriott C., Burke J.F. The origin of DNA associated with mucous glycoproteins in cystic fibrosis sputum. Eur. Respir. J. 3:1990;19-23.
46. Picot I., Das I., Reid L. Pus, deoxyribonucleic acid and sputum viscosity. Thorax. 33:1978;235-242.
47. Shak S., Capon D.J., Hellmiss R., Marsters S.A., Baker C.L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Natl. Acad. Sci. USA. 87:1990;9188-9192.
48. Rubin B.K., Ramirez O.E., Baharav A.L., Shak S., Toy K.J., Sinicropi D. The physical and transport properties of CF sputum after treatment with rhDNase. Pediatr. Pulmonol. 9S:1993;179.
49. Zahm J.M., Girod de Bentzmann S., Deneuville E., Perrot-Minnot C., Depret E., Pennaforte F., Roussey M., Puchelle E. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus. Eur. Respir. J. 8:1995;381-386.
50. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in cystic fibrosis. N. Engl. J. Med. 331:1994;637-648.
51. Vasconcellos C.A., Allen P.G., Wohl M., Drazen J.M., Janmey P.A. Reduction in sputum viscosity of cystic fibrosis sputum in vitro by gelsolin. Science. 263:1994;969-971.
52. Rubin B.K., Kater A.P., Dian T., Ramirez O.E., Tomkiewicz R.P., Goldstein A.L. Effects of thymosin β4 on cystic fibrosis sputum. Pediatr. Pulmon. 12S:1995;134-135.
53. Dasgupta B., Tomkiewicz R.P., De Sanctis G.T., Boyd W.A., King M. Rheological properties in cystic fibrosis airway secretions with combined rhDNase and gelsolin treatment. Singh M., Saxena V.P. Advances in Physiological Fluid Dynamics. 1996;74-78 Narosa, New Delhi.
54. J.D. Ferry, Molecular theory for undiluted polymers and concentrated solutions: Networks and entanglements. Viscoelastic Properties of Polymers, 2nd Edition, Wiley, New York, 1970, pp. 268-270.
55. King M., Dasgupta B., Tomkiewicz R.P., Brown N.E. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with rhDNase. Am. J. Respir. Crit. Care Med. 156:1997;173-177.
56. King M. Relationship between mucus viscoelasticity and ciliary transport in guaran gel/frog palate model system. Biorheology. 17:1980;249-254.
57. Wills P.J., Hall R.L., Chan W.M., Cole P.J. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J. Clin. Invest. 99:1997;9-13.
58. Feng W., Garrett H., Speert D.P., King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am. J. Respir. Crit. Care Med. 157:1998;710-714.
59. Ziment I. Mucokinetic agents. Respiratory Pharmacology and Therapeutics. 1978;Saunders, Philadelphia. pp. 60-104.
60. Winters S.L., Yeates D.B. Role of hydration, sodium, and chloride in regulation of canine mucociliary transport system. J. Appl. Physiol. 83:1997;1360-1369.
61. Lieberman J. Inhibition of protease activity in purulent sputum by DNA. J. Lab. Clin. Med. 70:1967;595-605.
62. Pavia D., Thompson D.L., Clarke S.W. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am. Rev. Respir. Dis. 117:1978;199-203.
63. Robinson M., Regnis J.A., Bailey D.L., King M., Bautovich G.J., Bye P.T.P. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 153:1996;1503-1509.
64. Robinson M., Hemming A.L., Regnis J.A., Wong A.G., Bailey D.L., Bautovich G.J., King M., Bye P.T.P. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 52:1997;900-903.
65. Barghouthi S., Guerdoud L.M., Speert D.P. Inhibition by dextran of Pseudomonas aeruginosa adherence to epithelial cells. Am. J. Respir. Crit. Care Med. 154:1996;1788-1793.
66. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 159:1999;1843-1848.
67. Shibuya Y., Wills P.J., Kitamura S., Cole P.J. The effects of lactose on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. Eur. Respir. J. 10:1997;321s.
68. Robinson M., Daviskas E., Eberl S., Baker J., Chan H.K., Anderson S.D., Bye P.T.P. Effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot study. Eur. Respir. J. 14:1999;678-685.
69. Feng W., Nakamura S., Sudo E., Lee M.M., Shao A., King M. Effects of dextran on tracheal mucociliary velocity in dogs in vivo. Pulmon. Pharmacol. Ther. 12:1999;35-41.
70. Feng W., Speert D.P., King M. Effect of dextran molecular weight on CF sputum rigidity: Further evidence for the mechanism of action. Pediatr. Pulmonol. 14S:1997;273.
71. Hirji M., Franklin R., Feng W., Boyd W.A., King M. Effect of oligomeric chain length on mucolytic and mucokinetic effects of oligosaccharides. Am. J. Respir. Crit. Care Med. 159:1998;A685.
72. Lee M.M., King M. Effect of low molecular weight heparin on the elasticity of dog mucus. Clin. Invest. Med. 21:1998;S102.
73. Lee M.M., Garrett H., Sudo E., Boyd W.A., King M. Mucociliary clearance increase due to low molecular weight heparin. Pediatr. Pulmonol. 17S:1998;386.
74. Sudo E., Boyd W.A., King M. Effect of dextran sulfate on tracheal mucociliary velocity in dogs. J. Aerosol Med. 13:2000;87-96.
75. King M., Sudo E., Lee M.M. Cilia and Mucus: From Development to Respiratory Defense. Salathé M. 2001;Marcel Dekker, New York. pp. 277-287.
76. Ahmed T., Garrigo J., Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. 329:1993;90-95.
77. Shute J., Forsyth C., Hockey P., Carroll M. Anti-inflammatory effects of inhaled nebulised heparin in adult CF patients: Results of a pilot study. Am. J. Respir. Crit. Care Med. 161:2000;A75.
78. Stockton P., Ledson M.J., Cowperthwaite C., Govin B., Gallagher M.J., Hart C.A., Walshaw M.J. A double blind placebo controlled crossover study of nebulised heparin therapy in adult cystic fibrosis patients. Pediatr. Pulmonol. S20:2000;278.
79. Dasgupta B., Tomkiewicz R.P., Boyd W.A., Brown N.E., King M. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro. Pediatr. Pulmonol. 20:1995;78-82.
80. Dasgupta B., King M. Reduction in viscoelasticity of cystic fibrosis sputum in vitro with combined treatment by Nacystelyn and rhDNase. Pediatr. Pulmonol. 22:1996;161-166.
81. F. Sun, S. Tai, T. Lim, U. Baumann, M. King, Additive effect of dornase alfa and nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum, Can. Respir. J. (2002) in press.
82. Hitchcock S.E., Carlsson L., Lindberg U. Depolymerization of F-actin by deoxyribonuclease I. Cell. 7:1976;531-542.
83. Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., Zhang Y., Elias J.A. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:1999;779-788.
84. Montserrat C., Merten M., Figarella C. Defective ATP-dependent mucin secretion by cystic fibrosis pancreatic epithelial cells. FEBS Lett. 393:1996;264-268.
85. Jaffé A., Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 31:2001;464-473.
86. Culic O., Erakovic V., Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429:2001;209-229.
87. Rubin B.K., Tamaoki J. Macrolides as biologic response modifiers. Curr. Opin. Invest. Drugs. 1:2000;169-172.
88. Anzueto A., Jubran A., Ohar J.A., Piquette C.A., Rennard S.I., Colice G., Pattishall E.N., Barrett J., Engle M., Perret K., Rubin B.K. Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial. J. Am. Med. Assoc. 278:1997;1426-1431.